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Objective: To compare the safety and effectiveness of fixed-combination regimes 
(  latanoprost–timolol and brinzolamide 1% compared to dorzolamide 1%/timolol and   latanoprost) 
in open-angle glaucoma patients after switching from a combination of three topical   antiglaucoma 
eye drops.
Methods: We conducted an open, randomized 12-week multicenter prospective study. We 
randomly allocated 39 patients who had been treated with three antiglaucoma eye drops 
(  prostaglandin F2α analogues plus beta-blockers and carbonic anhydrase inhibitors) into two 
groups. Group A (n = 20) were treated with latanoprost–timolol and brinzolamide 1% therapy and 
Group B (n = 16) were treated with dorzolamide 1%/timolol and latanoprost. Thirty-six patients 
completed all 12 weeks of this study. The major clinical parameters measured were intraocular 
pressure (IOP), conjunctive hyperemia, superficial punctate keratopathy and hyperpigmenta-
tion of eyelid at baseline, 4, and 12 weeks. Additionally noted were adverse events and patient 
preferences, measured using a questionnaire at study initiation and at 12 weeks.
Results: At baseline, IOPs were (Group A: 14.1 ± 2.9 mmHg, B: 14.5 ± 2.9 mmHg; P = 0.658), 
(Group A: 13.8 ± 2.6 mmHg, B: 14.3 ± 2.8 mmHg; P = 0.715) at 4 weeks, and (Group A: 
14.1 ± 2.7 mmHg, B: 14.2 ± 2.7 mmHg; P = 0.538) at 12 weeks. Among the groups, there was 
no significant difference at any time point after baseline (P = 0.923, 0.951, respectively). All 
adverse events were not remarkably different after therapy. In regards to patient preference 
before and after switching therapy, 10 patients (50%) in Group A and 10 patients (63%) in 
Group B preferred using fixed-combination eye drop therapy.
Conclusions: Effectiveness and safety were maintained in both groups after switching therapy. 
Overall, patients generally preferred using a fixed-combination therapy.
Keywords: glaucoma, latanoprost–timolol, dorzolamide–timolol, brinzolamide, fixed 
  combination, intraocular pressure
Introduction
High intraocular pressure (IOP) is a risk factor for developing visual field deficits 
in patients with various forms of glaucoma, including normal-tension glaucoma.1–3 
Chauhan et al reported that for every 1 mmHg increment in IOP, the risk of glaucoma 
progression increases by 19%.4 Reducing IOP is currently the only known strategy for 
preventing glaucoma progression.
Various kinds of antiglaucoma drugs have been successfully developed to date. 
However higher dose frequency, especially more than two administrations per day, 
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is usually associated with increased glaucoma medication 
nonadherence.5–9 Adherence to medication regimes is also 
attributable to side effects,10,11 the cost of medication,8,12 and 
noon-time doses.13,14 Recently, various fixed-combination 
therapies have become available. These have decreased the 
daily dose frequency and proved equally or more effective 
compared with combination therapy.15–19
Because of the benefits, a regime of fixed-combination 
therapy plus one antiglaucoma eye drop may be considered 
to be the most convenient and maximally tolerable manage-
ment strategy for glaucoma patients at present. To the best 
of our knowledge, there have been no studies which compare 
and evaluate which two administrations including fixed-
combination therapy is most safe and effective.
Latanoprost 0.005% was the first prostaglandin F2α 
analogue developed for use as a topical glaucoma medication 
and has been prescribed worldwide for more than 10 years. 
However, there have not yet been reports regarding which 
combination therapy; latanoprost–timolol + brinzolamide 
1% or dorzolamide 1%–timolol + latanoprost is superior in 
effectively and safely lowering IOP.
The aim of this study was to compare the   treatment 
regimes  of  latanoprost  0.005%–timolol  0.5%  plus 
  brinzolamide 1% (hereafter referred to as Regime A) versus 
dorzolamide 1%–timolol + latanoprost 0.005% (hereafter 
referred to as Regime B) to investigate their IOP reduction, 
ocular adverse effects, and patients’ response.
In this study, we conducted a randomized, controlled trial 
to compare the two regimens after switching from a combina-
tion of three topical antiglaucoma eye drops (prostaglandin 
F2α analogues plus beta-blockers and carbonic anhydrase 
inhibitors) to Regime A and Regime B in primary open-angle 
glaucoma patients.
Methods
Design
We conducted a randomized, open prospective multicenter 
study in which two groups were treated in parallel. The study 
received approval from the University Institutional Review 
Board in Hiroshima University and was conducted according 
to the tenets of the Declaration of Helsinki.
Patient selection
The purpose and nature of the trial was explained in detail to 
all patients and their informed consent was obtained. Patients 
were enrolled between April 2010 and January 2011 at three 
clinical sites in Japan, Tsukazaki Hospital, Baba Eye Clinic, 
and Hiroshima University Hospital. Inclusion criteria were: 
(1) primary open-angle glaucoma exhibiting characteristic 
glaucomatous visual-field loss and optic nerve head   damage; 
(2) exhibition of a stable IOP for more than 3 months mea-
sured by Goldmann applanation tonometer by the same 
ophthalmologist; (3) no history of fixed-combination therapy; 
and (4) patients that were treated with three antiglaucoma 
eye drops (various preparations of prostaglandin F2α 
  analogues + beta-blockers + carbonic anhydrase inhibitors).
Exclusion criteria were: (1) patients with congenital or 
narrow-angle glaucoma; (2) patients who had undergone 
ocular surgery including laser surgery within the previous 
6 months; (3) patients who have had any previous glaucoma 
surgery; (4) patients with ocular inflammation, neovascular 
glaucoma, or steroid-induced glaucoma; (5) patients with 
any other conditions that prevent use of the Goldmann 
applanation tonometer; (6) patients at risk of visual acuity 
and visual fields worsening during this study; and (7) allergy 
to preservatives. On the basis of these criteria, 39 patients 
were enrolled during the study period.
Procedures
Baseline visit assessments measured were: the best-corrected 
visual acuity; IOP by Goldmann applanation tonometer, slit-
lamp examination (including fundoscopy), results of visual 
field tests (Humphrey 30-2 or 24-2 SITA program, Humphrey 
Field Analyzer; Carl Zeiss Meditec, Dublin, CA) within sev-
eral months, age, sex, medical history, histories of cataract 
and glaucoma surgery, content of present antiglaucoma drugs, 
hyperpigmentation of eyelid, conjunctival hyperemia score 
and superficial punctate keratopathy (SPK, area–density [AD] 
classification).20 A written questionnaire for using the present 
eye drops was administered to check the adverse effects.
Patients were randomly allocated into two groups without 
a washout period: Group A: latanoprost–timolol (XalacomTM; 
Pfizer, Inc, New York, NY) + brinzolamide 1% (AzoptTM; 
Alcon Japan Limited, Tokyo, Japan) therapy (Regime A) 
and Group B: dorzolamide 1%–timolol (CosoptTM; Merck & 
Co, Inc, Whitehouse Station, NJ) + latanoprost (XalatanTM; 
Pfizer, Inc,) (Regime B). The various preparations of three 
antiglaucoma eye drops (prostaglandin F2α analogues + beta-
blockers + carbonic anhydrase inhibitors) are used.
Upon enrollment in the study, patients were advised to 
administer the medication according to the treatment regimen 
and were subsequently reevaluated at 4 and 12 weeks. Patients 
were instructed that latanoprost–timolol and latanoprost were 
to be self-administered once per day at night, and that brin-
zolamide and dorzolamide–timolol were self-administered 
twice per day. IOP was measured in the sitting position by 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
370
Nakakura et alClinical Ophthalmology 2012:6
Goldmann applanation tonometer by the same experienced 
ophthalmologists. IOP, hyperpigmentation of the eyelid, 
conjunctival hyperemia and SPK were evaluated at baseline, 
4, and 12 weeks. A questionnaire survey was evaluated at 
baseline and at 12 weeks. Each patient’s preference before 
and after switching treatments was evaluated at 12 weeks. 
Conjunctival hyperemia was classified using a four-grade 
photographic scale; slight (0), mild (+1), moderate (+2), and 
severe (+3). Superficial punctate keratopathy was assessed 
by fluorescein staining observed using a blue-free filter and 
evaluated using AD classification.20 The AD score is the add-
ing of the area score (0–3) and density score (0–3).
Adverse effects in the written questionnaire were 
evaluated by six questions indicating patient experience of 
stinging/burning, foreign body sensation, blurred vision, 
conjunctival hyperemia, frequency of forgetting adminis-
tration, and comfortableness when administered eye drops 
(Figure 1). Stinging/burning, foreign body sensation, blurred 
vision, and conjunctival hyperemia were judged by a three-
point response: yes, no, or neither. Frequency of forgetting 
Yes No Neither
Yes No Neither
Yes No Neither
Yes No Neither
Yes No Neither
Yes No Neither
Yes No Neither
Yes No Neither
Never Within two More than three
Comfortable Neither Uncomfortable
Before Same After
times per week times per week
Never Within two More than three
Comfortable Neither Uncomfortable
times per week times per week
Please check that the patient completes the questionnaire
A questionnaire before changing eye drops. Please co-operate.
Please check that the patient completes the questionnaire
A questionnaire after changing eye drops after 12 weeks. Please cooperate.
• Do you have “Stinging/burning” after
  administration?
• Do you have “Foreign body
  sensation” after administration?
• Do you have “Blurred vision” after
  administration?
• Do you have “Conjunctival
  hyperemia” after administration?
• How often do you forget
  administration per week?
• Comfortableness when you
  administered
• Do you have “Stinging/burning” after
  administration?
• Do you have “Foreign body
  sensation” after administration?
• Do you have “Blurred vision” after
  administration?
• Do you have “Conjunctival
  hyperemia” after administration?
• How often do you forget
  administration per week?
• Comfortableness when you
  administered
• Which do you prefer before or
  after changing therapy?
Figure 1 Questionnaire.
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administration was judged as never, once or twice per week, 
or more than three times per week. Comfortableness was 
judged by comfortable, neither comfortable nor uncom-
fortable, or uncomfortable. Patients who treated both eyes 
received the randomly chosen regimen in both eyes and the 
right eye was analyzed in this study.
Statistics
Statistical analyses were performed using JMP software 
(version 6.0.3; SAS Institute Inc, Cary, NC). Values are 
shown as mean ± standard deviation (SD). Values for patient 
characteristics were statistically analyzed by χ2 test and 
Student’s t-test. IOP differences between the groups were 
evaluated by Student’s t-test and one-way analysis of variance 
(ANOVA) was used to analyze the differences between IOP 
at individual time points before and after treatment in both 
groups. Patients’ distribution between regimes and settings 
were analyzed by the χ2 test. For the values regarding SPK 
(AD score) and conjunctival hyperemia, a Mann–Whitney U 
test was used between the two groups and a Kruskal–Wallis 
test was used to compare the differences between scores at 
individual time points before and after treatment in both 
groups. All questions in the questionnaire were evaluated by 
the χ2 test. P values less than 0.05 were considered statisti-
cally significant.
Results
Patients
Thirty-nine patients were enrolled in this study. Twenty 
out of 21 patients in Group A and 16 out of 18 patients in 
Group B followed the study to completion. One patient was 
lost at 12 weeks in Group A and two patients withdrew from 
Group B at 12 weeks because of hospitalization for heart 
disease (1 patient) and an orthopedic issue (1 patient).
Fifteen patients (n = 7 in Group A, n = 8 in Group B) 
from Tsukazaki Hospital, 11 patients from Baba Eye Clinic 
(n = 6 in Group A, n = 5 in Group B), and 10 patients from 
Hiroshima University Hospital (n = 7 in Group A, n = 3 in 
Group B) were enrolled (P = 0.514). Baseline demographic 
characteristics at 12 weeks of patients who completed the 
study are shown in Table 1. There were no statistically signifi-
cant differences between the two groups in age, the propor-
tion of males and females, visual acuity, degrees of visual 
field disturbance and lens (χ2 test and Student’s t-test).
Previous medications
Details of the various preparations of three antiglaucoma 
eye drops (prostaglandin F2α analogues + beta-blockers + 
carbonic anhydrase inhibitors) are shown in Table 1.
iOP
IOPs in Group A were 14.1 ± 2.9 mmHg at baseline, 
13.8 ± 2.6 mmHg at 4 weeks, and 14.1 ± 2.7 mmHg at 12 
weeks. There was no significant difference between each of 
the time points (one-way ANOVA; P = 0.923). IOPs in Group 
B were 14.5 ± 2.9 mmHg at baseline, 14.3 ± 2.8 mmHg at 
4 weeks and 14.2 ± 2.7 mmHg at 12 weeks. There was no 
significant difference between each of the time points (one-
way ANOVA; P = 0.951). Between the groups, there is no 
significant difference at baseline (P = 0.658), at 4 weeks 
(P = 0.715), or at 12 weeks (P = 0.538) by Student’s t-test 
(Figure 2). Power analysis of the test between the groups 
gave 0.05 (least significant number = 8664) at 4 weeks and 
0.07 (least significant number = 802) at 12 weeks.
Superficial punctate keratopathy  
and conjunctival hyperemia
The level of SPK as assessed by using the AD classification 
score and measuring conjunctival hyperemia was shown in 
Table 2. There was no significant difference at each of the 
time points either within or between the groups (Kruskal–
Wallis test and Mann–Whitney U test).
Hyperpigmentation of eyelid
At baseline, five patients in Group A and six patients in Group B 
showed hyperpigmentation of eyelid. At week 12, only one 
Table 1 Patient characteristics and previous medications
Characteristic Group A :  
N = 20  
Regime A
Group B :  
N = 16  
Regime B
P value
Age (yrs) 70.5 (12.1) 71.9 (12.8) 0.862b
Male/Female 9/11 10/6 0.296a
Mean  
Deviation (dB)
-10.8 (7.6) -15.2 (9.8) 0.077b
Visual Acuity 0.14 (0.33) 0.22 (0.76) 0.664b
Cataract Phakic l3/iOL 7 Phakic l3/iOL 3 0.279a
Combination (PG + β blocker + CAi)
Lat + Tim + Bri 5 6
Lat + TimG + Bri 5 4
Lat + Car + Bri 2 2
Lat + TimG + Dor 0 2
Lat + Tim + Dor 0 2
Bim + Tim + Bri 3 0
Bim + Tim + Dor 1 0
Taf + Tim + Bri 3 0
Lat + Car + Dor 1 0
Notes: Mean ± SD (standard deviation); aχ2 test; bStudent’s t-test.
Abbreviations: IOL, intraocular lens; Group A, latanoprost–timolol fixed combination 
+ brinzolamide (Regime A); Group B, dorzolamide 1%–timolol fixed combination + 
latanoprost (regime B); PG, prostaglandin F2α analogues; CAi, carbonic anhydrase 
inhibitors; Lat, latanoprost 0.005%; Tim, timolol maleate 0.5%; TimG, timolol maleate 
gel-forming ophthalmic solution 0.5%; Bri, brinzolamide 1.0%; Car, carteolol 2%; Dor, 
dorzolamide 1.0%; Bim, bimatoprost 0.03%; Taf, tafluprost 0.0015%.
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patient in Group A showed increasing hyperpigmentation 
(total of six patients). There were no remarkable changes 
in Group B.
results of the questionnaire
A 78-year-old female patient in Group A was excluded 
from the question “frequency of forgetting administration” 
because the drugs were administered by her family because 
of physical disability.
In the questionnaire, there was no significant difference 
either within or between the groups in any of the responses 
at baseline and 12 weeks. However a slight increase (three 
patients in Group A and two patients in Group B; P = 0.43 
and 0.48, respectively) was observed in responses to the 
question regarding experiences of “stinging/burning”. On the 
other hand, a slight decrease was observed (three patients in 
Group B; P = 0.43) in the question regarding experiences of 
“blurred vision”. No change was observed in the responses 
to the other questions (Table 3).
Patient preference in the questionnaire
At 12 weeks, two patients (10%) preferred combination therapy 
of three antiglaucoma eye drops, eight patients (40%) preferred 
the regimes equally, and ten patients (50%) preferred combina-
tion therapy using fixed-combination eye drop in Group A.
In Group B, no patients preferred combination therapy of 
three antiglaucoma eye drops. Six patients (37%) preferred 
the regimes equally and ten patients (63%) preferred com-
bination therapy using fixed-combination eye drops. There 
was no significant difference between the preferences of the 
groups (P = 0.394).
Discussion
In glaucoma patients, achieving a healthy IOP by mono-
therapy is the most desirable outcome, however, many 
patients need second-line antiglaucoma eye drops in order 
to combine different mechanisms of action. Second-line 
therapies are not uniform and various kinds of antiglau-
coma eye drops are prescribed in the United States.21 
Third-line therapy, however, almost always consists of 
prostaglandin F2α analogues with beta-blockers and car-
bonic anhydrase inhibitors. Nasser et al reported that 75% 
of ophthalmologists prescribed the combination of prosta-
glandin F2α analogues with dorzolamide 2%–timolol fixed 
combination (prostaglandin F2α analogues–timolol fixed 
combination is not yet available in the United States).21 
Meanwhile, various fixed-combination therapies have 
become available in European and Asian countries. Despite 
this, until this study no group had investigated or discussed 
whether third-line therapies including fixed combination 
were superior to other regimes. To make therapies which 
combine two different mechanisms-of-action drugs from 
three antiglaucoma eye drops is important for patients’ 
adherence.5–9
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Baseline 4 weeks
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14.1 ± 2.9
14.5 ± 2.9
14.3 ± 2.8
14.2 ± 2.7
14.1 ± 2.7
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Figure 2 Mean iOP at baseline, 4, and 12 weeks.
Notes: There were no significant differences at any of the time points either within or between the groups. Diamonds indicate Group A: latanoprost–timolol fixed 
combination + brinzolamide (Regime A). Squares indicate Group B: dorzolamide 1%–timolol fixed combination + latanoprost (regime B).
Table 2   Superficial  punctate  keratopathy  and  conjunctival 
hyperemia
Group A Group B P value
SPK (A + D score) 
Baseline
 
0.80 (1.40)
 
0.38 (0.81)
 
0.262b
4 w 0.55 (1.00) 0.13 (0.50) 0.108b
12 w 0.45 (0.94) 0.13 (0.50) 0.195b
P value 0.605a 0.426a
Hyperemia score
Baseline 0.16 (0.35) 0.17 (0.39) 0.767b
4 w 0.16 (0.35) 0.17 (0.39) 0.767b
12 w 0.11 (0.32) 0.11 (0.36) 0.815b
P value 0.868a 0.863a
Notes: aKruskal–Wallis test; bMann–Whitney U test.
Abbreviations: Group A, latanoprost–timolol fixed combination + brinzolamide 
(Regime A); Group B, dorzolamide 1%–timolol fixed combination + latanoprost 
(regime B).
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In our study, we evaluated two groups treated with 
regimes that both included latanoprost and achieved similar 
effects on IOP. Furthermore adverse effects were similar in 
both groups; therefore we recommend that either   combination 
is appropriate.
As for adverse effects, in self-reported “stinging/
burning”, a slight increase was observed in both groups, 
however no significant difference was observed between 
them at 12 weeks (P = 0.394). In line with this, Konstas 
et al reported in their crossover study that latanoprost and 
dorzolamide 2%–timolol fixed-combination treatment (18 of 
31 patients) reported more “burning/stinging” compared 
with a single dorzolamide 2%–timolol fixed combination 
(7 of 31 patients) or latanoprost–timolol fixed combination 
(4 of 31 patients) (P , 0.001).22 Shin et al also reported in 
2004 that more patients with dorzolamide 2%–timolol fixed 
combination reported “burning/stinging” compared with 
latanoprost–timolol fixed combination (11.7% vs 4.0%, 
respectively; P = 0.034).23 The mechanism of increasing 
sensations of “burning/stinging” is probably because of the 
low pH. Latanoprost–timolol fixed combination has a pH 
of 5.8–6.2 and dorzolamide 2%/timolol fixed combination 
has a pH of 5.5–5.8. They have a lower pH compared to 
latanoprost (pH 6.5–6.9), timolol (pH 6.5–7.5), brinzolamide 
(pH 7.5), and bimatoprost (pH 6.9–7.5). In addition to 
these drugs, clinicians also should take care to factor the 
sensations of other fixed-combination drugs. For example, 
bimatoprost–timolol fixed combination has a pH of 7.2–7.4, 
a brinzolamide–timolol fixed combination has a pH of 
6.5–7.5 and brimonidine–timolol fixed combination has a 
pH of 6.5–7.3.
A limitation of this study is that dorzolamide is used 
at 1% concentrations in Japan, however 2% solutions 
are used in European countries and the Americas. So 
our data may not directly compare with previous reports 
or future studies coming from those areas. However, 
Kitazawa et al reported in their dose-response study that 
the percentage reduction from baseline was greater after 
treatment with 0.5%, 1%, or 2% dorzolamide than after 
treatment with 0.2% dorzolamide.24 They concluded that 
IOP-lowering activity dose-response curve of dorzolamide 
may reach a plateau at concentrations equal to or above 
0.5%.   Furthermore, adverse effects of smarting and 
mild hyperemia were the most frequent following 2% 
dorzolamide (74.1% and 18.5%, respectively). Lippa et al 
also reported in the dose-response study that there is no 
Table 3 results of the questionnaire
Question Group A Group B
Baseline 12 w P value Baseline 12 w P value
Stinging/burning
Yes 5 8 0.43 4 6 0.48
No 14 10 11 10
Neither 1 2 1 0
Foreign body sensation
Yes 1 1 0.60 4 2 0.37
No 19 18 12 14
Neither 0 1 0 0
Blurred vision
Yes 8 8 1.00 5 2 0.43
No 11 11 9 11
Neither 1 1 2 3
Conjunctival hyperemia
Yes 3 0 0.18 1 0 0.60
No 16 18 14 15
Neither 1 2 1 1
Frequency of forgetting administration
None 16 17 0.83 14 14 1.00
Within two times per week 2 1 2 2
More than three times per week 1 1 0 0
Comfortableness
Comfortable 5 5 0.60 3 3 1.00
Neither 15 14 13 13
Uncomfortable 0 1 0 0
Notes: A 78-year-old female in Group A was excluded from the question “frequency of forgetting administration” because her drugs were administered by her family. 
Abbreviations: Group A, latanoprost–timolol fixed combination + brinzolamide (Regime A); Group B, dorzolamide 1%–timolol fixed combination + latanoprost (regime B).
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significant difference in IOP-lowering effects between 0.75, 
1.45, and 2% dorzolamide.25 Therefore, we consider that 
our results may be comparable with previous reports, and 
that 1%   dorzolamide may be superior to 2% dorzolamide 
in decreasing glaucoma medication nonadherence.
Our study reported short-term results in a small group of 
patients and was an open trial. Further long-term, large-scale, 
double-blinded, crossover studies are needed to compare the 
difference between the effects of Regime A and Regime B.
Conclusion
The efficiency and safety were maintained in both groups 
after switching therapy. Patients generally preferred using 
fixed-combination therapy compared with a combination of 
three antiglaucoma eye drops. Decreasing the numbers of 
eye drops using fixed-combination therapy may be useful 
for patients’ adherence.
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